GPC Biotech AG: Premium Company Profile

Questions: Discounts, Updates etc.

Price: $495.00

Publication Date: 2008-01-01

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

GPC Biotech (GPC), founded in 1997, has a business model relied on two pillars, as a service provider for preclinical research and as a product company with its own development pipeline. Later, the company changed its focus by developing a platform of base technologies, LeadCode, through collaborations with pharmaceutical partners and through the support of its own drug development projects.


Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Report Highlights
    GPC is a biopharmaceutical company focused on discovery, development and commercialization of new anticancer drugs, Cell Cycle Inhibitors and antibodies against MHC class II-positive tumor cells. It's most advanced product candidate satraplatin is currently in SPARC Phase III trial, for the treatment of hormone-refractory prostate cancer.

    The company's second lead product candidate, 1D09C3, is in Phase I clinical trials and is a monoclonal antibody indicated for the treatment of relapsed/refractory B-cell lymphomas, such as Hodgkin's and non-Hodgkin's lymphomas and chronic lymphocytic leukemia.

    The company's total revenues increased at a CAGR of 1.3% during 2002-2006, from $27.6 million to $29.1 million. This represents an absolute total growth of +$1.5 million during the historical period. The company's biggest contributor to revenue growth during 2002-2006 was license, collaboration and other revenues.


    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    Other users found this report page using the following search terms: GPC Biotech gpc biotech inc greg ag if mitotix hamm satraplatin bryostatin1

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.